Chi­nook de­lays topline kid­ney con­di­tion da­ta; Elu­minex ropes in $40M+ in a Se­ries B

Chi­nook’s read­out of its Phase III ALIGN tri­al of atrasen­tan, a po­ten­tial treat­ment for chron­ic kid­ney dis­eases, could be de­layed by about three months, the com­pa­ny said in an SEC fil­ing. The tri­al is look­ing at atrasen­tan in pa­tients with im­munoglob­u­lin A nephropa­thy (IgAN), a con­di­tion that can cause kid­ney dis­ease.

The com­pa­ny said the FDA rec­om­mend­ed that it add 12 weeks to an in­ter­im analy­sis of pa­tients’ urine pro­tein lev­els or pro­tein­uria. That would push back the pro­tein­uria da­ta to the fourth quar­ter of this year. The com­pa­ny said it’s plan­ning to meet with the agency to dis­cuss the rec­om­men­da­tion. — Kather­ine Lewin

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER